`ESTTA522251
`ESTTA Tracking number:
`02/19/2013
`
`Filing date:
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`Notice of Opposition
`
`Notice is hereby given that the following party opposes registration of the indicated application.
`Opposer Information
`
`Name
`Granted to Date
`of previous
`extension
`Address
`
`Novartis AG
`02/17/2013
`
`CH4002
`Basel,
`SWITZERLAND
`
`Attorney
`information
`
`Craig S. Mende
`Fross Zelnick Lehrman & Zissu, P.C.
`866 United Nations Plaza
`New York, NY 10017
`UNITED STATES
`cmende@fzlz.com,ghuron@fzlz.com Phone:2128135900
`Applicant Information
`
`Application No
`Opposition Filing
`Date
`Applicant
`
`85638848
`02/19/2013
`
`Publication date
`Opposition
`Period Ends
`
`08/21/2012
`02/17/2013
`
`Alpha Helix Inc.
`Suite 3206 3750 Las Vegas Blvd
`Las Vegas, NV 89158
`UNITED STATES
`Goods/Services Affected by Opposition
`
`Class 005.
`All goods and services in the class are opposed, namely: Dietary supplements for boosting pre-
`workout energy; Nutritional supplements for boosting pre-workout energy
`
`Grounds for Opposition
`
`Priority and likelihood of confusion
`Dilution
`
`Trademark Act section 2(d)
`Trademark Act section 43(c)
`
`Marks Cited by Opposer as Basis for Opposition
`
`U.S. Registration
`No.
`Registration Date
`
`3767722
`
`03/30/2010
`
`Word Mark
`
`VOLTAREN
`
`Application Date
`
`07/10/2009
`
`Foreign Priority
`Date
`
`NONE
`
`
`
`Design Mark
`
`Description of
`Mark
`Goods/Services
`
`U.S. Registration
`No.
`Registration Date
`
`Word Mark
`Design Mark
`Description of
`Mark
`Goods/Services
`
`NONE
`
`Class 005. First use:
`Pharmaceutical preparations, namely, anti-inflammatory preparations and
`analgesics
`
`960282
`
`06/05/1973
`
`VOLTAREN
`
`NONE
`
`Application Date
`
`04/28/1972
`
`Foreign Priority
`Date
`
`NONE
`
`Class U018 (International Class 005). First use:
`ANTIPHLOGISTIC AND ANTIRHEUMATIC
`
`Attachments
`
`79072252#TMSN.jpeg ( 1 page )( bytes )
`Notice of Opposition Novartis AG v. Alpha Helix (VOLTAREN v. VOLTAGEN)
`(F1175063).PDF ( 23 pages )(805791 bytes )
`
`The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address
`record by First Class Mail on this date.
`
`Certificate of Service
`
`Signature
`Name
`Date
`
`/Craig S. Mende/
`Craig S. Mende
`02/19/2013
`
`
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`
`
`Opposition No.
`
`NOTICE OF OPPOSITION
`
`---------------------------------------------------------------x
`Novartis AG,
`
`
`
`
`:
`
`
`
`
`
`
`
`:
`
`
`
`Opposer,
`
`
`:
`
`
`
`
`
`
`
`:
`
`- against -
`
`
`
`
`:
`
`
`
`
`
`
`
`:
`Alpha Helix Inc.,
`
`
`
`
`:
`
`
`
`
`
`
`
`:
`
`
`
`Applicant.
`
`
`:
`---------------------------------------------------------------x
`
`
`Opposer Novartis AG, a Swiss corporation with a principal business address of CH 4002,
`
`Basel, Switzerland, believes that it would be damaged by the issuance of a registration for the
`
`trademark VOLTAGEN as applied for in intent-to-use Application Serial No. 85638848 (the
`
`“Application”) filed on May 30, 2012 by Alpha Helix Inc. (“Applicant”), and therefore opposes
`
`the same. The specific grounds for this opposition are as follows:
`
`
`
`FACTS
`
`A.
`
`
`Opposer and Its Famous VOLTAREN Mark
`
`1.
`
`Opposer and its predecessors-in-interest have used the mark VOLTAREN for
`
`many years in connection with healthcare products, including anti-inflammatory and pain relief
`
`products, throughout the United States.
`
`2.
`
`Through significant expenditures of time, effort and money promoting Opposer’s
`
`VOLTAREN mark and the associated logo (the “VOLTAREN mark”) and the products sold
`
`thereunder, as well as the success of VOLTAREN products in the marketplace over many years,
`
`{F1138365.3 }
`
`
`
`Opposer’s VOLTAREN mark has come to identify Opposer’s goods exclusively and uniquely,
`
`has become a well-known and famous mark of Opposer, and represents an enormous goodwill.
`
`3.
`
`Opposer Novartis A.G. and (under Opposer’s authorization) its U.S. subsidiary
`
`Novartis Corporation (together, “Novartis”) also own federal registrations for the VOLTAREN
`
`mark:
`
`I U.S. Reg. No. 3767722 for VOLTAREN & Design for “Pharmaceutical
`preparations, namely, anti-inflammatory preparations and analgesics” in
`International Class 5, issued in 2010; and
`
`0 U.S. Reg. No. 0960282 for VOLTAREN for “Antiphlogistic and antirheumatic”
`in International Class 5, issued in 1973.
`
`Print-outs from the United States Patent and Trademark Office’s database showing the title and
`
`status of these registrations are attached at Exhibit A. These registrations are valid, subsisting
`
`and in full force and effect, and constitute evidence of the validity of the marks shown therein
`
`and of Novartis’ exclusive right to use the marks in connection with the goods identified in the
`
`registrations.‘
`
`B.
`
`Applicant’s Application for VOLTAGEN
`
`4.
`
`Upon information and belief, Applicant is a Nevada corporation located and doing
`
`business at Suite 3206, 3750 Las Vegas Blvd., Las Vegas, NV 89158.
`
`5.
`
`Upon information and beliefi on May 30, 2012, long after Novartis’ VOLTAREN
`
`mark was first used in commerce, and long after Novartis’ VOLTAREN mark became famous
`
`and came to identify the goods of Novartis and its predecessors exclusively, Applicant filed the
`
`1 U.S. Reg. No. 0960282, owned by Novartis Corporation, has become incontestable and
`therefore constitutes conclusive evidence of the validity of the mark shown therein and of the
`exclusive right to use the VOLTAREN mark in connection with the goods identified in the
`registration.
`
`{F} 138365 3 }
`
`
`
`Application to register the mark VOLTAGEN for “Dietary supplements for boosting pre-workout
`
`energy; Nutritional supplements for boosting pre-workout energy” in International Class 5.
`
`6.
`
`Upon information and belief, Applicant did not begin selling products bearing the
`
`VOLTAGEN mark in the United States until the Summer of 2012.
`
`7.
`
`Applicant’s VOLTAGEN mark is highly similar to Novartis’ VOLTAREN mark
`
`in sight, sound and commercial impression. In fact, the only difference between VOLTAREN
`
`and VOLTAGEN is the substitution of one letter (a “G” for an “R”) within the eight letters in
`
`each mark.
`
`8.
`
`The goods identified in the Application for the VOLTAGEN mark are in the same
`
`international class and are related to the healthcare products sold under Novartis’ VOLTAREN
`
`mark.
`
`9.
`
`Upon information and belief, Applicant’s VOLTAGEN products are being and/or
`
`will be sold by the same types of retailers, including pharmacies, at which Novartis’
`
`VOLTAREN products are sold.
`
`10.
`
`Applicant has also copied additional indicia associated with the VOLTAREN
`
`mark and products, including by use of VOLTAGEN product packaging featuring the color
`
`orange, which is similar to the coloring of Novartis’ VOLTAREN packaging.
`
`l 1.
`
`In View of the similarities of the parties’ respective marks, goods and trade
`
`channels, Applicant’s use of the VOLTAGEN mark in connection with the goods identified in
`
`the Application is likely to cause confusion and/or mistake as to the source or sponsorship of
`
`those goods, including by deceiving consumers into believing that Applicant’s goods come from,
`
`or are approved by, the maker of products sold under the VOLTAREN mark.
`
`(F11383653 )
`
`
`
`12. When Applicant filed the Application to register the VOLTAGEN mark, it was on
`
`constructive notice of Novartis’ prior and exclusive rights in the VOLTAREN mark by virtue of
`
`Novartis’ federal trademark registrations therefor, pursuant to Section 22 of the Lanham Act, 15
`
`U.S.C. § 1072.
`
`13.
`
`Upon information and belief, when Applicant filed the Application to register the
`
`VOLTAGEN mark, it had actual knowledge of the prior use of the VOLTAREN mark in
`
`connection with the goods offered by Novartis and its predecessors-in-interest.
`
`14.
`
`Registration to Applicant of the VOLTAGEN mark would be inconsistent with
`
`Novartis’ prior exclusive rights in the VOLTAREN mark, would threaten destruction of
`
`Novartis’ investment and goodwill in its long-established and valuable VOLTAREN mark, and
`
`would dilute and impair the distinctiveness of Novartis’ famous VOLTAREN mark and the
`
`ability of the VOLTAREN mark to identify the goods offered by Novartis under the
`
`VOLTAREN mark.
`
`LANHAM ACT SECTION 2(d) — LIKELIHOOD OF CONFUSION
`
`FIRST CLAIM FOR RELIEF
`
`15.
`
`Opposer incorporates by reference paragraphs 1 through 14 above.
`
`16.
`
`Opposer’s VOLTAREN mark has been used continuously since a date prior to any
`
`priority date upon which Applicant may rely with respect to its VOLTAGEN mark.
`
`17.
`
`Applicant’s VOLTAGEN mark is highly similar to Opposer’s VOLTAREN mark.
`
`18.
`
`Applicant’s goods to be offered under the VOLTAGEN mark are closely related
`
`to goods sold under Opposer’s VOLTREN mark and, upon information and belief, will be sold to
`
`the same customers or types of customers to whom Opposer’s goods are sold under the
`
`VOLTAREN mark.
`
`{FH38365 3}
`
`
`
`19.
`
`Based on the similarity of the marks and goods, consumers are likely to be
`
`confused and/or deceived into falsely believing that the goods offered by Applicant under the
`
`VOLTAGEN mark originate with or are approved or authorized by the maker of VOLTAREN
`
`products, or that there is some relationship between Applicant and Opposer or the goods of
`
`Applicant sold under the VOLTAGEN mark and the goods of Opposer sold under the
`
`VOLTAREN mark. Any use of the VOLTAGEN mark by Applicant in connection with the
`
`goods identified in the Application is therefore likely to cause confusion, cause mistake, or to
`
`deceive consumers in violation of Section 2(d) of the Lanham Act, 15 U.S.C. § l052(d).
`
`20.
`
`By reason of the foregoing, Opposer will be damaged by the registration of the
`
`VOLTAGEN mark to Applicant.
`
`SECOND CLAIM FOR RELIEF
`
`LANHAM ACT SECTION 43§c) — DILUTION
`
`21.
`
`Opposer incorporates by reference paragraphs 1 through 20 above.
`
`22.
`
`Opposer’s VOLTAREN mark is federally-registered, distinctive, used nationally
`
`in commerce and promoted throughout the United States for many years, and is instantly
`
`recognized by consumers as a symbol of Opposer or its goods.
`
`23.
`
`Since long before any priority date upon which Applicant may rely, Opposer’s
`
`VOLTAREN mark has become famous.
`
`24.
`
`Applicant’s use and registration of the VOLTAGEN mark will damage Opposer
`
`by trading on the enormous goodwill and reputation associated with Opposer’s VOLTAREN
`
`mark and diluting its distinctiveness and ability to identify the goods offered by Opposer.
`
`[F1138365 3 )
`
`
`
`25.
`
`Thus, Applicant’s use and registration of the VOLTAGEN mark in connection
`
`with the goods identified in the Application will cause dilution of Opposer’s VOLTAREN mark
`
`in violation of Sections 13(a) and 43(c) of the Lanham Act, 15 U.S.C. §§ l063(a), 1125(0).
`
`26.
`
`By reason of the foregoing, Opposer will be damaged by the registration of
`
`Applicant’s VOLTAGEN mark.
`
`WHEREFORE, it is respectfully requested that this opposition be sustained and that the
`
`registration sought by the Application be denied in its entirety.
`
`Dated: New York, New York
`February 19, 2013
`
`_
`Respectfully submitted,
`
`FROSS ZELNTCK LEHRMAN & ZISSU, P.C.
`
`Craig Mende (cmende@fzlz.com)
`Giselle C.W. Huron (ghuron@fzlz.com)
`866 United Nations Plaza
`
`New York, New York 10017
`Tel: (212) 813-5900
`Attorneys for Opposer Novartis AG
`
`(FH38365 3 }
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on this 19th day of February, 2013, a true and correct copy of the
`foregoing NOTICE OF OPPOSITION was served by U.S. first class mail on App1icant’s
`counsel of record:
`
`TRAVIS TUNNELL
`ANDERSON DAILEY LLP
`
`2002 SUMIVHT BLVD STE 1250
`
`ATLANTA, GA 30319-6402
`
`Q H
`
`Giselle C.W. I--Iuron
`
`{F1 I38361] I
`
`
`
`EXHIBIT A
`
`
`
`Generated on 2013-02-19T11:52:28.316-05:00
`
`Generated on:
`
`This page was generated by TSDR on 2013-02-19 11:52:28 EST
`
`Mark:
`
`VOLTAREN
`
`v It
`
`'
`
`US Serial
`Number:
`
`79072252
`
`"'°P"°°“°“
`Filing Date:
`
`Jul 10 2009
`'
`’
`
`US Registration
`Number:
`
`3767722
`
`R°9“‘”‘_“°" Mar. 30,2010
`Date.
`
`Register:
`
`Principal
`
`Mark Type:
`
`Trademark
`
`Status:
`
`Registered. The registration date is used to determine when post-registration
`maintenance documents are due.
`
`Status Date:
`
`Mar. 30, 2010
`
`Publication
`Date:
`
`Jan. 12,2010
`
`Mark Literal
`Elements:
`
`VOLTAREN
`
`Standard
`Character Claim:
`
`No
`
`Mark Information
`
`Mark Drawing
`Type:
`
`3 — AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/
`LETTER(S)/NUMBER(S)
`
`Color(s) Claimed:
`
`Color is not claimed as a feature of the mark.
`
`Design Search
`code(5):
`
`02.01.33 - Stick figures;Grotesque men formed by letters, numbers, punctuation
`or geometric shapes
`04.07.03 - Geometric shapes forming a person;Person formed by geometric
`shapes;Geometric figures representing a person;Geometric figures or
`combinations of geometric figures representing a person
`26.01.21 - Circles that are totally or partially shaded.
`26.03.21 - Ovals that are completely or partially shaded
`26.17.09 - Bands, curved;Bars, curved;Curved line(s), band(s) or bar(s);Lines,
`curved
`
`Related Properties Information
`
`
`
`International
`
`Registration
`Number:
`
`1011414
`
`International
`Registration Date:
`
`1111' 10’ 2009
`
`
`Claimed Ownership 0960282
`of US Registrations:
`1753115 L696”
`
`Goods and Services
`
`Note:
`
`The following symbols indicate that the registrant/owner has amended the goods/services:
`
`o
`o
`
`o
`
`- Brackets [..] indicate deleted goods/services;
`- Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit
`of incontestability; and
`- Asterisks *..* identify additional (new) wording in the goods/services.
`
`For:
`
`Pharmaceutical preparations, namely, anti-inflammatory preparations and
`.
`analgesics
`
`International Class: 005 - Primary Class
`
`U.S Class:
`
`006, 018, 044, 046, 051, 052
`
`Class Status:
`
`ACTIVE
`
`Basis:
`
`66(a)
`
`Basis Information (Case Level)
`
`Filed Use:
`
`Filed ITU:
`
`Filed 44D:
`
`Filed 44E:
`
`No
`
`No
`
`No
`
`No
`
`Currently Use: No
`
`Amended Use: No
`
`Currently ITU: No
`
`Amended ITU: No
`
`Currently 44D: No
`
`Amended 44D: No
`
`Currently 44E: No
`
`Amended 44E: No
`
`Filed 66A:
`
`Yes
`
`Currently 66A: Yes
`
`Filed No Basis: No
`
`Currently No
`Basis:
`
`No
`
`Current Owner(s) Information
`
`Owner Name: Novartis AG
`
`CH-4002 Basel
`Owner Address: SWITZERLAND
`
`
`
`Legal Entity
`Type:
`
`CORPORATION
`
`State or Country
`Where
`
`Organized:
`
`SWITZERLAND
`
`Attorneylcorrespondence Information
`
`Attorney of Record
`
`Attorney Name:
`
`Maury M. Tepper, III
`
`Correspondent
`
`Correspondent
`NamelAddress:
`
`Maury M. Tepper, III
`Tepper & Eyster, PLLC
`3724 Benson Drive
`
`Raleigh, NORTH CAROLINA 27609
`UNITED STATES
`
`Phone:
`
`919-861-8903
`
`Fax:
`
`919-861-8913
`
`Correspondent e-
`mail:
`
`mte
`
`2
`
`_
`;
`2 @ -
`er
`tel law com
`
`Correspondent e-
`mall Authorized: No
`
`Domestic Representative - Not Found
`
`Prosecution History
`
`Date
`
`Description
`
`:L°n:::in9
`
`Jul. 22, 2010
`
`Jul. 22, 2010
`
`Jul. 01, 2010
`
`FINAL DISPOSITION NOTICE SENT TO IB
`
`FINAL DISPOSITION PROCESSED
`
`68359
`
`FINAL DISPOSITION NOTICE CREATED, TO BE SENT
`TO IB
`
`Mar. 30, 2010
`
`REGISTERED-PRINCIPAL REGISTER
`
`Jan. 12, 2010
`
`MAILED
`
`OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-
`
`Jan. 12, 2010
`
`PUBLISHED FOR OPPOSITION
`
`Dec. 08, 2009
`
`LAW OFFICE PUBLICATION REVIEW COMPLETED
`
`73797
`
`Dec. 08, 2009
`
`ASSIGNED TO LIE
`
`Nov. 19, 2009
`
`Nov. 17, 2009
`
`Nov. 17, 2009
`
`APPROVED FOR PUB - PRINCIPAL REGISTER
`
`TEAS/EMAIL CORRESPONDENCE ENTERED
`
`CORRESPONDENCE RECEIVED IN LAW OFFICE
`
`Nov. 17. 2009
`
`TEAS RESPONSE TO OFFICE ACTION RECEIVED
`
`73797
`
`88889
`
`88889
`
`
`
`Nov. 06, 2009
`
`REFUSAL PROCESSED BY IB
`
`Oct. 26, 2009
`
`Oct. 26, 2009
`
`Oct. 14, 2009
`
`ATTORNEY REVOKED AND/OR APPOINTED
`
`TEAS REVOKE/APPOINT ATTORNEY RECEIVED
`
`NON—FINAL ACTION MAILED - REFUSAL SENT TO IB
`
`Oct. 14, 2009
`
`REFUSAL PROCESSED BY MPU
`
`Oct. 14, 2009
`
`NON—FINAL ACTION (IB REFUSAL) PREPARED FOR
`REVIEW
`
`Oct. 13,2009
`
`NON—FINAL ACTION WRITTEN
`
`Oct. 09, 2009
`
`ASSIGNED TO EXAMINER
`
`Sep. 29, 2009
`
`Sep.25,2009
`
`Sep. 24, 2009
`
`APPLICATION FILING RECEIPT MAILED
`
`NEW APPLICATION OFFICE SUPPLIED DATA
`ENTERED IN TRAM
`
`SN ASSIGNED FOR SECT 66A APPL FROM IB
`
`67445
`
`76839
`
`76839
`
`International Registration Information (Section 66a)
`
`International
`
`Registration
`Number:
`
`1011414
`
`International
`Registration Date:
`
`Jul. 10,2009
`
`lntl. Registration
`Status:
`
`REQUEST FOR
`EXTENSION OF
`PROTECTION PROCESSED
`
`I Date P‘
`
`I
`
`gtatusz
`
`Sep. 24,2009
`
`Notification of
`
`Designation Date:
`
`Sep. 24,2009
`
`First Refusal Flag:
`
`Yes
`
`D t
`fA t
`t"
`3 ggteaigma '° Mar. 24,2011
`
`TM Staff and Location Information
`
`TM Staff Information - None
`
`File Location
`
`Current Location:
`
`PUBLICATION AND ISSUE
`SECTION
`
`Date in Location: Mar. 30, 2010
`
`
`
`Generated on 2013-02-19T11253113749-05:00
`
`Generated on:
`
`This page was generated by TSDR on 2013-02-19 11:53:13 EST
`
`Mark:
`
`VOLTAREN
`
`us Serial Number: 72422688
`
`A°P"°3‘a‘g} F‘""9 Apr. 28,1972
`
`Us Registration
`Number:
`
`960282
`
`Re istration Date‘
`9
`'
`
`Jun 05 1973
`'
`’
`
`Register:
`
`Principal
`
`Mark Type:
`
`Trademark
`
`Status:
`
`The registration has been renewed.
`
`Status Date:
`
`Aug. 04, 2003
`
`Mark Information
`
`Mark Literal
`Elements:
`
`VOLTAREN
`
`Standard
`Character Claim:
`
`No
`
`""""" °'°‘”"‘9
`Type:
`
`1 — TYPESET WORD(S) /LETTER(S) /NUMBER(S)
`
`Foreign Information
`
`Foreign Registration
`Number:
`
`172661
`
`Foreign
`Registration Date: Oct’ 28’ 1958
`
`Foreign
`App|icationIRegistration SVVITZERLAND
`Country:
`
`Goods and Services
`
`Note:
`
`The following symbols indicate that the registrant/owner has amended the goods/services:
`
`-
`o
`
`o
`
`- Brackets [..] indicate deleted goods/services;
`- Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit
`of incontestability; and
`- Asterisks *..* identify additional (new) wording in the goods/services.
`
`
`
`For:
`
`ANTIPHLOGISTIC AND ANTIRHEUMATIC
`
`International Class: 005
`
`U.S Class:
`
`018 - Primary Class
`
`Class Status:
`
`ACTIVE
`
`Basis:
`
`44(e)
`
`Basis Information (Case Level)
`
`Filed Use:
`
`Filed ITU:
`
`Filed 44D:
`
`No
`
`No
`
`No
`
`Currently Use: No
`
`Amended Use: No
`
`Currently ITU: No
`
`Amended ITU: No
`
`Currently 44D: No
`
`Amended 44D: N0
`
`Filed 44E:
`
`Yes
`
`Currently 44E: Yes
`
`Amended 44E: No
`
`Filed 66A:
`
`No
`
`Currently 66A: No
`
`Filed No Basis: No
`
`Currently No
`Basis:
`
`No
`
`Current Owner(s) Information
`
`Owner Name: NOVARTIS CORPORATION
`
`608 FIFTH AVENUE
`
`Owner Address: NEW YORK, NEW YORK 10020
`UNITED STATES
`
`Legal Entity
`Type:
`
`CORPORATION
`
`State or Country NEW YORK
`Where Organized:
`
`Attorneylcorrespondence Information
`
`Attorney of Record - None
`
`Correspondent
`
`correspondent
`NamelAddress:
`
`Maury M. Tepper, III
`Tepper & Eyster, PLLC
`3724 Benson Drive
`.
`Ra1e1gh, NORTH CAROLINA 27609
`UNITED STATES
`
`Phone:
`
`919-861-8903
`
`Fax:
`
`919-861-8913
`
`Correspondent e- mte ; I; er@tei”1aw_c0m
`mall:
`
`Correspondent e- Yes
`mall Authorized.
`
`Domestic Representative - Not Found
`
`
`
`Prosecution History
`
`Date
`
`Description
`
`Proceeding
`Number
`
`76293
`
`76293
`
`67826
`
`Jul. 20, 2011
`
`ASSIGNMENT OF OWNERSHIP NOT UPDATED
`AUTOMATICALLY
`
`Jul. 13, 2011
`
`AUTOMATICALLY
`
`ASSIGNMENT OF OWNERSHIP NOT UPDATED
`
`Dec. 22, 2010
`
`ASSIGNMENT OF OWNERSHIP NOT UPDATED
`AUTOMATICALLY
`
`Dec. 15, 2010
`
`ASSIGNMENT OF OWNERSHIP NOT UPDATED
`AUTOMATICALLY
`
`Feb. 18, 2010
`
`ASSIGNMENT OF OWNERSHIP NOT UPDATED
`AUTOMATICALLY
`
`Jan. 22, 2010
`
`REVIEW OF CORRESPONDENCE COMPLETE
`
`Jan. 22, 2010
`
`CASE ASSIGNED TO POST REGISTRATION
`PARALEGAL
`
`Dec. 02, 2009
`
`Jun. 17, 2009
`
`Sep. 02, 2008
`
`Dec. 04, 2004
`
`CASE ASSIGNED TO POST REGISTRATION
`PARALEGAL
`
`TEAS CHANGE OF CORRESPONDENCE RECEIVED
`
`CASE FILE IN TICRS
`
`TEAS CHANGE OF CORRESPONDENCE RECEIVED
`
`Nov. 18, 2004
`
`PAPER RECEIVED
`
`Aug. 04, 2003
`
`REGISTERED AND RENEWED (SECOND RENEWAL - 10
`
`YRS)
`
`Aug. 04, 2003
`
`REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9
`GRANTED
`
`May 22, 2003
`
`REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9
`FILED
`
`May 21, 2003
`
`Oct. 28, 1996
`
`Sep. 09, 1996
`
`Oct. 27, 1993
`
`TEAS SECTION 8 & 9 RECEIVED
`
`REGISTERED - SEC. 15 ACKNOWLEDGED
`
`REGISTERED - SEC. 15 AFFIDAVIT FILED
`
`REGISTERED AND RENEWED (FIRST RENEWAL — 10
`
`YRS)
`
`Sep. 07, 1993
`
`REGISTERED - SEC. 9 FILED/CHECK RECORD FOR
`SEC. 8
`
`
`
`Jun. 04, 1979
`
`REGISTERED - SEC. 8 (6-YR) ACCEPTED
`
`Maintenance Filings or Post Registration Information
`
`Aff'd
`'t
`f
`c°nti'nE‘;i Sse:
`
`-
`Sectlon 8 - Accepted
`
`Affidavit of
`lncontestability:
`
`.
`Secnon 15 ' Accepted
`
`Renewal Date:
`
`Jun. 05, 2003
`
`TM Staff and Location Information
`
`TM Staff Information - None
`
`File Location
`
`Current Location: SCANNING ON DEMAND
`
`Date in Location: Sep. 02, 2008
`
`Assignment Abstract of Title Information
`
`.T°‘a'
`Assignments:
`
`10
`
`Assignment 1 of 10
`
`Summary
`
`Registrant:
`
`CIBA-GEIGY LIMITED
`
`C
`
`_
`°""°V°"°°'
`
`CERTIFICATE FROM THE REGISTRY OF COMMERCE OF THE CANTON
`OF BASLE, SHOWING CHANGE OF NAME ENTERED OCT. 21, 1970.
`
`ReeIlFrame:
`
`0205/0123
`
`Pages:
`
`1
`
`Date Recorded: Apr. 06, 1971
`
`No Supporting Documents
`
`Assignor
`
`Name:
`
`CIBA LIMITED
`
`Execution Date: Mar. 29, 1971
`
`Legal Entity Type: UNKNOWN
`
`State or Country
`
`Where
`Organized:
`
`3°C Where Orgamzed
`u
`
`-
`
`Name:
`
`CIBA-GEIGY LIMITED
`
`Assignee
`
`Legal Entity Type: UNKNOWN
`
`State or Country
`Where
`
`-
`No Place Where Orgamzed
`
`
`
`Organized:
`
`Found
`
`Address:
`
`No Assignee Address Found
`
`Correspondent
`
`Correspondent
`Name:
`
`HARRY GOLDSMITH
`
`Correspondent
`Address:
`
`556 MORRIS AVE.
`
`SUMMIT, NJ 07901
`
`Domestic Representative - Not Found
`
`Assignment 2 of 10
`
`Conveyance:
`
`ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL
`
`Ree|IFrame:
`
`0249/0418
`
`Pages:
`
`3
`
`Date Recorded:
`
`Mar. 13, 1974
`
`Supporting
`Documents:
`
`No Supporting Documents
`
`Name:
`
`CIBA-GEIGY LIMITED
`
`Execution Date: Jan. 23, 1974
`
`Assignor
`
`Legal Entity Type:
`
`CORPORATION
`
`State or Country
`Where
`
`Organized:
`
`SWITZERLAND
`
`Name:
`
`CIBA-GEIGY CORPORATION
`
`Assignee
`
`Legal Entity Type:
`
`CORPORATION
`
`State or Country
`Where
`
`NEW YORK
`
`Organized:
`
`Address:
`
`444 SAW MILL RIVER ROAD
`
`ARDSLEY, NEW YORK 10502
`
`Correspondent
`
`Correspondent
`Name:
`
`Correspondent
`Address:
`
`GEORGE M. DOHERTY
`
`444 SAW MILL RIVER ROAD
`
`ARDSLEY, NY 10502
`
`Domestic Representative - Not Found
`
`Assignment 3 of 10
`
`Conveyance:
`
`CHANGE OF NAME
`
`ReelIFrame:
`
`1873/0581
`
`Pages:
`
`
`
`Date Recorded: Mar. 12, 1999
`
`supporting
`Documents:
`
`assignment-tm—1873-0581.pdf
`
`CIBA-GEIGY
`Name: N Execution Date: Dec. 26, 1996
`
`Assignor
`
`Legal Entity Type: CORPORATION
`
`State or Country
`
`Where
`Organized:
`
`11:10 P2306 Where Orgamzed
`mm
`
`-
`
`Name:
`
`NOVARTIS CORPORATION
`
`Assignee
`
`Legal Entity Type: CORPORATION
`
`Ad“'°s5‘
`
`564 MORRIS AVNEUE
`SUMMIT NEW JERSEY 07901
`
`State or Country
`Where
`Organized:
`
`NEW YORK
`
`Correspondent
`
`°°"°"’°""°"‘ BARRY A SOLOMON
`Name:
`'
`
`NOVARTIS CORPORATION
`
`Correspondent
`Address:
`
`PATENT AND TRADEMARK DEPARTMENT
`564 MORRIS AVENUE
`
`SUMMIT, NJ 07901-1027
`
`Domestic Representative - Not Found
`
`Assignment 4 of 10
`
`Conveyance:
`
`CHANGE OF NAME
`
`ReellFrame:
`
`1900/0069
`
`Pages:
`
`11
`
`Date Recorded: Oct. 16, 1998
`
`5“PP°'“"9
`Documents:
`
`assignment-tm-1900-0069.pdf
`
`Assignor
`
`Name:
`
`CIBA-GEIGY
` ON
`
`Legal Entity Type: CORPORATION
`
`Execution Date: Dec. 26, 1996
`
`State or Country
`Where
`Organized:
`
`NEW YORK
`
`Name:
`
`NOVARTIS CORPORATION
`
`Assignee
`
`
`
`Legal Entity Type:
`
`CORPORATION
`
`State or Country
`Where
`
`NEW YORK
`
`Organized:
`
`Address:
`
`564 MORRIS AVENUE
`
`SUMMIT, NEW JERSEY 07901
`
`Correspondent
`
`Correspondent
`Name:
`
`NOVARTIS CORPORATION
`
`Correspondent
`Address:
`
`BARRY A. SOLOMON, ESQ.
`564 MORRIS AVENUE
`
`SUMMIT, NJ 07901
`
`Domestic Representative - Not Found
`
`Assignment 5 of 10
`
`Conveyance:
`
`LICENSE
`
`Ree|IFrame:
`
`4088/0466
`
`Date Recorded:
`
`Oct. 30, 2009
`
`Supporting
`Documents:
`
`assignment-tm-4088-0466.pdf
`
`Pages:
`
`Name:
`
`
`NOVARTIS AG
`
`Execution Date: Mar. 04, 2008
`
`Assignor
`
`Legal Entity Type:
`
`CORPORATION
`
`State or Country
`Where
`
`Organized:
`
`SWITZERLAND
`
`Name:
`
`NOVARTIS CONSUMER
` EALTHINC.
`
`
`_
`Execution Date. Mar. 04, 2008
`
`Legal Entity Type:
`
`CORPORATION
`
`State or Country
`Where
`
`Organized:
`
`NEW JERSEY
`
`Name:
`
`ENDO PHARMACEUTICALS INC.
`
`Assignee
`
`Legal Entity Type:
`
`CORPORATION
`
`State or Country
`Where
`
`Organized:
`
`PENNSYLVANIA
`
`Address:
`
`100 ENDO BOULEVARD
`
`CHADDS FORD, PENNSYLVANIA 19317
`
`Correspondent
`
`
`
`°°"°s"°"°'°"* GUY DONATIELLO
`Name:
`
`Correspondent
`Address:
`
`100 ENDO BOULEVARD
`CHADDS FORD, PA 19317
`
`Assignment 6 of 10
`
`Domestic Representative - Not Found
`
`C
`
`_
`°""°Va"°°'
`
`CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES
`TRADEMARKS (EXCLUSIVELY LICENSED TRADEMARKS)
`
`Reel/Frame:
`
`4149/0283
`
`Pages:
`
`6
`
`Date Recorded:
`
`Feb. 13,2010
`
`S”PP°'”"9
`Documents:
`
`assiggment-tm-4149-0283.pdf
`
`ENDO PHARMACEUTICALS
`Name: T“? Execution Date: Oct. 16, 2009
`INC.
`
`Assignor
`
`Legal Entity Type: CORPORATION
`
`State or Country
`Where
`Organized:
`
`DELAWARE
`
`Assignee
`
`Name:
`
`
`JPMORGAN CHASE BANK N.A. AS ADMINISTRATIVE AGENT
`
`Legal Entity Type:
`
`State or Country
`
`Where
`
`Organized:
`
`UNITED STATES
`
`Address.
`'
`
`10 SOUTH DEARBORN
`CHICAGO, ILLINOIS 60603
`
`Correspondent
`
`°°"°‘°'P°"“°"‘ DUSAN CLARK, ESQ.
`Name:
`
`C
`
`°'A'§:f:::°"‘
`'
`
`SIDLEY AUSTIN LLP
`717 N. HARWOOD ST., SUITE 3400
`DALLAS, TX 75201
`
`Assignment 7 of 10
`
`Domestic Representative - Not Found
`
`C
`
`_
`°""°V"‘"°°'
`
`CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES
`TRADEMARKS (EXCLUSIVELY LICENSED TRADEMARKS)
`
`ReellFrame:
`
`4423/0376
`
`Pages:
`
`7
`
`Date Recorded: Dec. 01, 2010
`
`
`
`Supporting
`Documents:
`
`assignment-tm—4423-O376.pdf
`
`Assignor
`
`Name:
`
` Execution Date: Nov. 30, 2010
`INC.
`
`Legal Entity Type:
`
`CORPORATION
`
`State or country
`Where
`
`Organized:
`
`DELAWARE
`
`Assignee
`
`Name:
`
`JPMORGAN CHASE BANK N.A. AS ADMINISTRATIVE AGENT
`
`Legal Entity Type:
`
`NATIONAL BANKING
`
`ASSOCATION
`
`s*““° °' °°"""V
`Where
`organized:
`
`UNITED STATES
`
`Address:
`
`10 SOUTH DEARBORN
`
`CHICAGO, ILLINOIS 60603
`
`Correspondent
`
`Correspondent
`Name:
`
`DUSAN CLARK, ESQ.
`
`Correspondent
`Address:
`
`SIDLEY AUSTIN LLP
`
`717 N. HARWOOD ST., SUITE 3400
`DALLAS, TX 75201
`
`Assignment 8 of 10
`
`Domestic Representative - Not Found
`
`Conveyance:
`
`RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME
`4149/283
`
`Reel/Frame:
`
`4428/0839
`
`Date Recorded:
`
`Dec. 09, 2010
`
`Pages:
`
`4
`
`Supporting
`Documents:
`
`assigggent-tm-4428-0839.pdf
`
`Assignor
`
`
`
`JPMORGAN CHASE BANK
`
`N.A. AS ADMINISTRATIVE Execution Date: Nov. 30, 2010
`AGENT
`
`Name:
`
`Legal Entity Type:
`
`NATIONAL ASSOCIATION
`
`State or Country
`Where
`
`Organized:
`
`UNITED STATES
`
`Name:
`
`ENDO PHARMACEUTICALS INC.
`
`Assignee
`
`
`
`Legal Entity Type: CORPORATION
`
`State or Country
`Where
`Organized:
`
`DELAWARE
`
`A°""°5s‘
`
`100 ENDO BLVD.
`CHADDS FORD, PENNSYLVANIA 19317
`
`Correspondent
`
`°°"°"°°""°"* DUSAN CLARK ESQ
`Name:
`’
`
`‘
`
`°°"°"°°"d°"‘
`Ad"'°ss‘
`
`SIDLEY AUSTIN LLP
`717 N HARWOOD ST SUITE 3400
`DALLAS, TX 75201
`
`Assignment 9 of 10
`
`Domestic Representative - Not Found
`
`Conveyance:
`
`SECURITY INTEREST IN EXCLUSIVELY LICENSED TRADEMARKS
`
`ReelIFrame:
`
`4577/0228
`
`Pages:
`
`6
`
`Date Recorded:
`
`Jul. 07, 2011
`
`aSsigT_1gent-tm-4577-O228.pdf
`
`Assignor
`
`Name: Execution Date:
`
`Jun. 17, 2011
`
`Legal Entity Type: CORPORATION
`
`State or Country
`Where
`Organized:
`
`DELAWARE
`
`Assignee
`
`Name_
`'
`
`
`MORGAN STANLEY SENIOR FUNDING INC. AS ADMINISTRATIVE
`AGENT
`
`Legal Entity Type: CORPORATION
`
`State or Country
`Where
`Organized:
`
`DELAWARE
`
`Address_
`
`1 PIERREPONT PLAZA
`BROOKLYN, NEW YORK 11201
`
`Correspondent
`
`°°"°‘P°"“°"‘ DUSAN CLARK, ESQ.
`Name:
`
`°°'A"‘;‘f::s"s“_°"‘
`'
`
`SIDLEY AUSTIN LLP
`717 N. HARWOOD ST., SUITE 3400
`DALLAS, TX 75201
`
`
`
`Assignment 10 of 10
`
`Domestic Representative - Not Found
`
`C
`
`_
`°""°V" "°°'
`
`RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED
`TRADEMARKS RECORDED AT REEL/FRAME 4423/376
`
`ReelIFrame:
`
`4580/0431
`
`Pages:
`
`5
`
`Date Recorded:
`
`Jul. 12, 2011
`
`assignrnent-tm-4530-043 I .Qdf
`
`Assignor
`
`
`
`JPMORGAN CHASE BANK
`
`N.A. AS ADMINISTRATIVE Execution Date: Jun. 17, 2011
`AGENT
`
`Name:
`
`Legal Entity Type:
`
`NATIONAL BANKING
`
`ASSOCIATION
`
`State °' °°” "W
`Where
`organized:
`
`UNITED STATES
`
`Name:
`
`ENDO PHARMACEUTICALS INC.
`
`Assignee
`
`Legal Entity Type: CORPORATION
`
`State or Country
`Where
`Organized:
`
`DELAWARE
`
`Add
`
`_
`'°‘°“'
`
`100 ENDO BOULEVARD
`CHADDS FORD, PENNSYLVANIA 19317
`
`Correspondent
`
`°°"rj:fn°e':d°"‘ DUSAN CLARK, ESQ.
`
`°°;{§:f::s‘f°"‘
`'
`
`SIDLEY AUSTIN LLP
`717 N. HARWOOD ST., SUITE 3400
`DALLAS, TX 75201
`
`Domestic Representative - Not Found